机译:在第一中研究和在健康受试者的实验人内毒性期间和在实验人内毒性期间的安全性,耐受性和药代动力学/药效学抗体Adrecizumab
Department of Intensive Care Medicine Radboud Center for Infectious Diseases (RCI)Radboud;
Department of Intensive Care Medicine Radboud Center for Infectious Diseases (RCI)Radboud;
Department of Anesthesia Burn and Critical CareUniversity Hospitals Saint‐Louis – Lariboisière AP;
Department of Intensive Care Medicine Radboud Center for Infectious Diseases (RCI)Radboud;
Department of Intensive Care Medicine Radboud Center for Infectious Diseases (RCI)Radboud;
Department of Anesthesia Burn and Critical CareUniversity Hospitals Saint‐Louis – Lariboisière AP;
Department of Intensive Care Medicine Radboud Center for Infectious Diseases (RCI)Radboud;
Department of Intensive Care Medicine Radboud Center for Infectious Diseases (RCI)Radboud;
adrecizumab; adrenomedullin; antibody; endotoxaemia; sepsis; shock;
机译:肾上腺髓质蛋白抗体Adrecizumab在一本人的研究中以及在健康受试者中的实验性人内毒性期间的安全性,耐受性和药代动力学/药效学
机译:在首次人体研究中,人类抗IL-6单克隆抗体(sirukumab)在健康受试者中的药代动力学,药效学和安全性。
机译:人类抗IL-6单克隆抗体(西鲁单抗)在健康受试者中的药代动力学,药效学和安全性
机译:在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性,耐受性,药效动力学和药代动力学
机译:阿法曲巴帕在健康受试者和慢性肝病患者中的药代动力学/药效学分析
机译:肾上腺髓质素抗体adrecizumab在人体实验中和人类内毒素血症实验中的安全性耐受性和药代动力学/药效学
机译:在健康成人对象中,ALPN-101的安全性,耐受性,药代动力学和AlPN-101的药效学和药效学的第一次人体研究